Search Results

You are looking at 21 - 30 of 62 items for :

  • "peptide receptor radionuclide therapy (PRRT)" x
  • Refine by Access: All content x
Clear All
Free access

Mojun Zhu, Karl R Sorenson, Rebecca Liu, Bonnie E Gould Rothberg, and Thorvardur R Halfdanarson

( Fendrich et al. 2009 , Falconi et al. 2016 , Howe et al. 2020 ). Systemic therapy for advanced and metastatic disease can consist of somatostatin analogs, peptide receptor radionuclide therapy (PRRT), molecular therapies targeting the mammalian

Free access

Maria Chiara Zatelli, Elia Guadagno, Erika Messina, Fabio Lo Calzo, Antongiulio Faggiano, Annamaria Colao, and NIKE Group

are no randomized studies indicating that platinum is the treatment of choice for these tumors. Thang and coworkers explored peptide receptor radionuclide therapy (PRRT) efficacy in G3 NEN, evaluated by response evaluation criteria in solid tumors

Free access

Johannes Hofland, Aura D Herrera-Martínez, Wouter T Zandee, and Wouter W de Herder

, Strosberg et al. 2017 b ) recommend SSAs as first-line therapy in CS in stage IV NET patients. Second-line options include IFN, locoregional therapy, SSA dose increase, everolimus or peptide receptor radionuclide therapy (PRRT) using radiolabeled SSAs

Free access

J R Strosberg, M Cives, J Hwang, T Weber, M Nickerson, C E Atreya, A Venook, R K Kelley, T Valone, B Morse, D Coppola, and E K Bergsland

radionuclide therapy (PRRT) vs octreotide 60mg long-acting repeatable (LAR) in patients with metastatic, progressive midgut NETs and demonstrated a 79% reduction in the risk for progression (HR=0.209, P <0.0001) ( Strosberg et al. 2015 ). Similarly, the

Free access

Clemens Kratochwil, Ruben López-Benítez, Walter Mier, Sabine Haufe, Berend Isermann, Hans-Ulrich Kauczor, Peter L Choyke, Uwe Haberkorn, and Frederik L Giesel

risk factors . European Journal of Nuclear Medicine and Molecular Imaging 35 1847 – 1856 . doi:10.1007/s00259-008-0778-1 . Bodei L Pepe G Paganelli G 2010 Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with

Free access

M Cives, M Ghayouri, B Morse, M Brelsford, M Black, A Rizzo, A Meeker, and J Strosberg

and radiosensitizing capecitabine), 11 had prior everolimus, 6 had prior sunitinib, 2 had prior peptide receptor radionuclide therapy (PRRT) and 9 had prior investigational agents (including pasireotide, bevacizumab and ganitumab). The median time from

Free access

Sten Myrehaug, David L Chan, Victor Rodriguez-Freixinos, Hans Chung, Julie Hallet, Calvin Law, Chirag Patel, Laurent Milot, John Hudson, Hanbo Chen, and Simron Singh

treatment with full protocol dose of 7.5 mg po daily everolimus. This full protocol dose of 7.5 mg was chosen extrapolating from the tolerability seen in a preceding trial of everolimus and peptide receptor radionuclide therapy (PRRT) ( Claringbold & Turner

Free access

David Taïeb, Christelle Fargette, Abhishek Jha, and Karel Pacak

option to beta emitters in peptide receptor radionuclide therapy (PRRT). In a recent study which included nine PPGL patients using actinium-225, partial response was observed in 50% of cases (objective response in 87.5%) ( Yadav et al. 2022 ). Seven out

Open access

Anna Angelousi, Aimee R Hayes, Eleftherios Chatzellis, Gregory A Kaltsas, and Ashley B Grossman

required to treat patients who fail to respond to TKIs or experience unacceptable toxicity. New-generation targeted therapies such as immunotherapy and peptide receptor radionuclide therapy (PRRT) may be promising but require prospective randomised trials

Free access

Joanna Grey and Kym Winter

. 2016 ); the use of peptide receptor radionuclide therapy (PRRT) using radiolabelled somatostatin analogues (Nbib1915485 and even immunotherapy (Nbib3072160 The emotional impact of pre-operative symptoms and